Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
1999-09-01
2003-04-29
Park, Hankyel T. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C424S130100, C424S140100, C424S143100, C424S145100, C530S388220, C530S388230, C530S389200, C530S391100
Reexamination Certificate
active
06555320
ABSTRACT:
BACKGROUND
1. Technical Field
The invention relates to methods and materials for evaluating rheumatoid arthritis as well as for determining an individual's predisposition to have severe rheumatoid arthritis disease.
2. Background Information
Rheumatoid arthritis (RA) affects individuals in the prime of their life and is feared because of its potential to cause chronic pain and irreversible damage of tendons, ligaments, joints, and bones. The symmetrical involvement of small peripheral joints has an enormous impact on hand and foot functions and poses therapeutic challenges that cannot be easily overcome by joint replacement. Also, systemic manifestations of RA are not rare and can range from relatively minor problems, such as rheumatoid nodules, to life-threatening organ disease.
In addition, RA is a systemic inflammatory disease that primarily manifests itself as synovial inflammation of diarthrodial joints. The typical histopathological changes include dense infiltration of the synovial membrane by mononuclear cells, neoangiogenesis, and hypertrophy and hyperplasia of the synovial lining (Harris E D (ed); Rheumatoid Arthritis, Philadelphia, WB Saunders Co., pp.3-212 (1997); and Hale L P, Haynes B F: Pathology of rheumatoid arthritis and associated disorders. Arthritis and Allied Conditions. A textbook of Rheumatology. Edited by Koopman W J. Baltimore, Williams & Wilkins, pp.993-1016 (1997)). The etiopathogenesis of the syndrome is not understood. Several lines of evidence support a central role of T lymphocytes in the disease-specific pathogenic events (Todd, et al.
Science
, 240:1003-1009 (1988); Panayi, et al.,
Arthritis Rheum
, 35:729-735 (1992); and Goronzy J J, Weyand C M:
Rheum Dis Clin North Am
, 21:655-674 (1995)). An alternative hypothesis, namely, that macrophages are the pivotal cell type in rheumatoid synovitis, has also been proposed (Firestein G S, Zvaifler N J:
Arthritis Rheum
33:768-773 (1990); and Burmester, et al.,
Arthritis Rheum
, 40:5-18 (1997)). Whether only T cells or only macrophages or both are the causative elements in RA remains a matter of controversy (Feldmann, et al.,
Cell
, 85:307-310 (1996); and Fox,
Arthritis Rheum
40:598-609 (1997)).
RA is primarily a clinical diagnosis. Symmetrical joint involvement, dominant manifestations in peripheral joints, rheumatoid factor production, and the formation of rheumatoid nodules are considered when the diagnosis is made (Arnett, et al.,
Arthritis Rheum
. 31:315-324 (1988)). The histological appearance of the synovium varies quite extensively and the pathological findings are usually not helpful in distinguishing RA from other inflammatory arthropathies (Hale L P, Haynes B F: Pathology of rheumatoid arthritis and associated disorders. Arthritis and Allied Conditions. A textbook of Rheumatology. Edited by Koopman W J. Baltimore, Williams & Wilkins, pp.993-1016 (1997)). In addition, no information is available on the mechanisms underlying the topographical arrangement of the inflammatory infiltrate in the rheumatoid synovium.
Therapeutic management of RA has steadily improved over the last decades, mostly due to the recognition that destruction caused by chronic inflammation is irreversible and that only early and aggressive intervention can enhance therapeutic benefit. Consequently, RA patients are now being treated early in the disease course and disease modifying agents are widely used. Despite these successes, major challenges remain. Presently, no curative intervention is available, side effects of therapies are significant, and the disease may still progress while the patient is being treated.
SUMMARY
The invention involves methods and materials for evaluating rheumatoid arthritis in a patient. Specifically, the invention provides methods and materials for classifying a rheumatoid arthritis condition as diffuse, follicular, or granulomatous. In addition, the invention provides methods and materials for determining if an individual suffering from a rheumatoid arthritis condition will develop severe disease. Useful indicators for severe disease include, without limitation, subcutaneous nodule formation (nodularity) and extra-articular involvement.
The invention is based on the discovery that the level of particular cytokines within tissue or the histological appearance of tissue or both can be used to classify a rheumatoid arthritis condition as diffuse, follicular, or granulomatous. This classification is important since granulomatous patients are more susceptible to severe rheumatoid arthritis disease. Severe rheumatoid arthritis disease can involve, without limitation, major organ involvement, which can be life threatening, and major joint destruction, which can be crippling. Thus, proper classification of a granulomatous rheumatoid arthritis condition can help provide clinicians and patients with information that can be used to determine adequate treatments.
Specifically, the invention involves analyzing a synovial tissue biopsy for particular cytokines such as IL-4, IL-10, and IFN-&ggr;, or for particular histological characteristics, or both. For example, a patient can be classified as having a diffuse condition when tissue from that patient contains low levels of IL-4, IL-10, and IFN-&ggr;, or as having a follicular condition when tissue from that patient contains high levels of IL-10 and IFN-&ggr; and low levels of IL-4. A particular level of a particular cytokine can be determined to be high or low based on the levels measured from various populations. Such populations can include, without limitation, populations of patents with a diffuse condition, follicular condition, or granulomatous condition, patients with subcutaneous nodule formation, patients with extra-articular involvement, patients with major joint destruction, and healthy individuals.
The invention also is based on the discovery that patients presenting similar rheumatoid arthritis symptoms can have different levels of particular cytokines within their tissue or different histological appearance of their tissue. Thus, determining the tissue cytokine profile or the histological characteristics of a synovial tissue sample from a patient can be used to determine the proper treatment protocol. For example, two patients having similar rheumatoid arthritis symptoms may have different levels of IL-10 within their tissue. The patient with low levels may benefit from a treatment of IL-I 0 while the patient with high levels of IL-10 may benefit from treatment with IL-10 inhibitors such as anti-IL-10 antibodies. Thus, determining the tissue cytokine profile or the histological characteristics of a tissue sample from a patient can help provide clinicians and patients with information that can be used to determine adequate treatments.
In addition, the invention is based on the discovery that the predisposition to develop severe disease can be determined in patients classified as having diffuse or follicular disease by analyzing the patient's HLA-DRB1 alleles or frequency of CD4
+
/CD28
null
cells or both. Determining a patient's predisposition to develop severe disease is important since it allows clinicians and patients to plan and treat accordingly. Again, severe rheumatoid arthritis disease can involve, without limitation, extra-articular involvement and major joint destruction. Moreover, analyzing a patient's HLA-DRB1 alleles and/or frequency of CD4
+
/CD28
null
cells can be used to determine whether a patient classified as having diffuse or follicular disease with a propensity for severe disease will have major organ damage, major joint destruction, or both.
Specifically, the invention involves determining whether a patient having a diffuse or follicular condition has zero, one, or two HLA-DRB1 alleles that are associated with RA and/or whether that patient has an elevated frequency of CD4
+
/CD28
null
cells. For example, HLA-DRB1 alleles that are associated with RA can be any allele having a polymorphism associated with rheumatoid arthritis including HLA-DRB1 alleles that encode polypeptides
Goronzy Jorg J.
Weyand Cornelia M.
Brown Stacy S.
Fish & Richardson P.C. P.A.
Mayo Foundation for Medical Education and Research
Park Hankyel T.
LandOfFree
Methods and materials for evaluating rheumatoid arthritis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and materials for evaluating rheumatoid arthritis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and materials for evaluating rheumatoid arthritis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3030594